Gentamicin-induced correction of CFTR, function in patients with cystic fibrosis and CFTR stop mutations

New England Journal of Medicine

Volumn 349, Issue 15, 2003, Pages 1433-1441

  Wilschanski, Michael ^a   Yahav, Yaacov ^c   Yaacov, Yasmin ^a   Blau, Hannah ^d   Bentur, Lea ^e   Rivlin, Joseph ^f   Aviram, Micha ^g   Bdolah Abram, Tali ^h   Bebok, Zsuzsa ⁱ   Shushi, Liat ^h   Kerem, Batsheva ^h   Kerem, Eitan ^a,b  

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^e RAMBAM MEDICAL CENTER   (Israel)

^f CARMEL MEDICAL CENTER   (Israel)

^g BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^h HEBREW UNIVERSITY OF JERUSALEM   (Israel)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE; CHLORIDE CHANNEL; CRYSELLE; ESTROSTEP 21; ESTROSTEP FE; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETHINYLESTRADIOL PLUS NORGESTREL; GENE PRODUCT; GENTAMICIN; ISOPRENALINE; LOESTRIN 21 1 20; LOESTRIN 21 1.5 30; LOESTRIN FE 1 20; LOESTRIN FE 1.5 30; LOW OGESTREL; MESTRANOL PLUS NORETYNODREL; MICROGESTIN FE 1 20; MICROGESTIN FE 1.5 30; MONONESSA; MOVE TO 1443; NECON 1 35; NECON 7 7 7; NEOCON 0.5 35; NORINYL 1 35; NORTEL 1 35; NORTREL 0.5 35; NORTREL 7 7 7; ORTHO NOVUM 7 7 7; ORTHO TRI CYCLEN LO; PLACEBO; SPRINTEC; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; ZOVIA 1 35SE;

ADOLESCENT; ADULT; ARTICLE; CFTR GENE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ELECTROPHYSIOLOGY; FEMALE; GENE; GENE CONTROL; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNOFLUORESCENCE; MALE; NOSE MUCOSA; OPEN STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STOP CODON; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CODON, NONSENSE; CROSS-OVER STUDIES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; GENE DELETION; GENOTYPE; GENTAMICINS; HUMANS; MEMBRANE POTENTIALS; MIDDLE AGED; NASAL MUCOSA;

EID: 0141863491     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa022170     Document Type: Article

References (27)

1. Welsh MJ, Tsui L-C, Boat TF, Beaudet AL. Cystic fibrosis. In: Scriver C, Beaudet AL, Valle D, eds. The metabolic and molecular bases of inherited disease. 7th ed. Vol. 3. New York: McGraw-Hill, 1995:3799-876.
2. Cystic fibrosis mutation database. (Accessed September 12, 2003, at http://www.genet.sickkids.on.ca./cftr/.)
3. The Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med 1993;329:1308-13.
4. Shoshani T, Augarten A, Gazit E, et al. Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am J Hum Genet 1992;50:222-8.
5. Kopelowitz J, Hampe C, Goldman R, Reches M, Engelberg-Kulka H. Influence of codon context on UGA suppression and readthrough. J Mol Biol 1992;225:261-9.
6. Poole ES, Brown CM, Tate WP. The identity of the base following the stop codon determines the efficiency of in vivo translational termination in Escherichia coli. EMBO J 1995;14:151-8.
7. Bonetti B, Fu L, Moon J, Bedwell DM. The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae. J Mol Biol 1995;251:334-45.
8. Gorini L, Kataja E. Phenotypic repair by streptomycin of defective genotypes in E. coli. Proc Natl Acad Sci U S A 1964;51:487-93.
9. Ruusala T, Kurland CG. Streptomycin preferentially perturbs ribosomal proofreading. Mol Gen Genet 1984;198:100-4.
10. Burke JE, Mogg AE. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res 1985; 13:6265-72.
11. Buchanan JH, Stevens A, Sidhu J. Aminoglycoside antibiotic treatment of human fibroblasts: intracellular accumulation, molecular changes and the loss of ribosomal accuracy. Eur J Cell Biol 1987;43:141-7.
12. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996;2:467-9.
13. Bedwell DM, Kaenjak A, Benos DJ, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997;3:1280-4.
14. - secretion in cystic fibrosis bile ductular cells. Hepatology 2002;35:95-104.
15. Barton-Davis E, Cordier L, Shorturma D, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999;104:375-81.
16. Keeling KM, Brooks DA, Hopwood JJ, Li P, Thompson JN, Bedwell DM. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet 2001;10:291-9.
17. Helip-Wooley A, Park MA, Lemons RM, Thoene JG. Expression of CTNS alleles: subcellular localization and aminoglycoside correction in vitro. Mol Genet Metab 2002;75: 128-33.
18. Sleat DE, Sohar I, Gin RM, Lobel P. Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. Eur J Paediatr Neurol 2001;5:Suppl A:57-62.
19. Keeling KM, Bedwell DM. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med 2002;80:367-76.
20. Wilschanski M, Famini C, Blau H, et al. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 2000;181: 860-5.
21. Clancy JP, Bebok Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001;163:1683-92.
22. Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995;6:445-55.
23. Fleiss JL. The design and analysis of clinical experiments. New York: John Wiley, 1986:263-71.
24. Highsmith WE, Burch LH, Zhou Z, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994;331:974-80.
25. Wilschanski M, Famini H, Strauss-Liviatan N, et al. Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur Respir J 2001;17:1208-15.
26. Rubenstein RC, Zeitlin PL. A pilot trial of oral sodium 4-phenylbutyrate (Buphenyl) in ΔF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998;157:484-90.
27. Wagner KR, Hamed S, Hadley DW, et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001;49:706-11.